Fundz

Fundz Deep Dive

Everything you need to win Recipharm — in one platform.

Who to reach, what to say, and why now on Recipharm — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on Recipharm — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.

ReciBioPharm Awarded Three-Year Grant from Bill & Melinda Gates Foundation for RNA Manufacturing

Jan 20, 2025•over 1 year ago

Contract Type

contract

SwedenManufacturingBiotechnologyPharmaceutical

Description

ReciBioPharm, a division of Recipharm, has been awarded a three-year grant from the Bill & Melinda Gates Foundation to support the global deployment of xRNA Continuous Manufacturing technologies to Low- and Middle-Income Countries with a focus on the development of inline Process Analytical Technologies and predictive analytics software. The platform aims to improve the scalability, quality, and accessibility of RNA-based medicines and will help advance its goal of developing fully integrated, continuous processes.

Company Information

Company

Recipharm

Location

Sweden

About

Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing over 7,400 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices.

Predictive Intelligence
Strategic

ML-powered predictions for Recipharm's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.